On January 3, 2025, the Ministry of Health of Ukraine registered three full-spectrum medical cannabis extracts under the Curaleaf brand with varying THC and CBD ratios. The manufacturer listed in the registry is the Spanish company Medalchemy S.L., which is 97.5% indirectly owned by Curaleaf Holdings Inc., while the applicant was the Ukrainian company Pharmdistribution LLC. The registered substances are intended for the manufacture of prescription drugs in licensed pharmacies. Thus, products of an international corporation whose financing history and ownership structure, according to financial reports, state registries, and journalistic investigations, show ties to Russian business have entered the Ukrainian market.
Who is Behind Curaleaf
Curaleaf is led by Boris Jordan, Chairman and CEO, who controls approximately 69% of shareholder voting power through multiple-voting shares. Jordan built a significant part of his career in Russia: he headed the Gazprom-Media holding and NTV television channel, worked in the oil sector, and founded the Sputnik investment group. According to a Guardian investigation, Jordan acknowledged that he previously maintained close personal relations with Vladimir Putin.
Russian Capital in the Company's History
The involvement of Russian capital in the business began before Curaleaf went public. In 2013, PalliaTech — Curaleaf's predecessor — raised $10 million from Jordan's Sputnik Group and its Russian partners in exchange for a 35% stake. Later, according to Forensic News investigative materials, funds for acquiring PalliaTech shares and financing Jordan-linked structures were provided by Cetus Investments Limited, associated with Roman Abramovich: $14 million was documented in 2016 and $10 million in 2017. In 2018, Curaleaf received $85 million in secured debt financing from Cetus. In December 2022, Jordan confirmed to Bloomberg that Abramovich had financed Curaleaf in the early stages of its development.
Sanctioned Bank and Shareholders
An additional episode involves the Moscow Credit Bank (MCB), which is subject to sanctions by the US, EU, UK, and Ukraine. According to an investigation by The Newsground, in 2020 the bank received 15.5 million Curaleaf shares as collateral under a deal worth approximately $77 million; following the imposition of sanctions, the stipulated buyback did not take place, and in December 2023 the bank retained the securities in its ownership — their market value at the time was around $58 million. Curaleaf stated that it had frozen the voting rights on this block of shares and restricted their transfer, sale, and dividend payouts. Major shareholders also included Andrei Blokh, former president of Sibneft and an associate of Abramovich: as of May 2026, he owned 17.6% of the corresponding class of shares, and personal sanctions by Ukraine were imposed on him in October 2022.
Company Position
Curaleaf denies any current Russian influence on the company's operations, stating that it does not conduct business in Russia and does not receive funding from Russian oligarchs after going public. Boris Jordan has stated that he sold his Russian assets long ago and has no ties to the Russian authorities. At the same time, these statements do not negate the documented facts of Russian investors' participation in the company's establishment, financing from structures associated with Abramovich, and the transfer of shares to the sanctioned MCB. It is these circumstances that form the Russian context of the corporation whose products are now registered in Ukraine.